Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sNSE:SAIPARENT +5.28%14 EV-to-FCF is -38.89 as of Aug. 09, 2026. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 565 Drug Manufacturers companies, Sai Parenteral's ranks worse than 176990.97% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sai Parenteral's's Enterprise Value is ₹27,006 Mil.
Sai Parenteral's's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was ₹-694 Mil. Therefore, Sai Parenteral's's EV-to-FCF for today is -38.89.
The historical rank and industry rank for Sai Parenteral's's EV-to-FCF or its related term are showing as below:
NSE:SAIPARENT'
s EV-to-FCF Range Over the Past 10 Years
Min: -38.89 Med: 78.62 Max: 89.86
Current: -38.89
During the past 3 years, the highest EV-to-FCF of Sai Parenteral's was 89.86. The lowest was -38.89. And the median was 78.62.
NSE:SAIPARENT's EV-to-FCF is ranked worse than 100% of 565
companies
in the Drug Manufacturers industry
Industry Median: 21.83
vs NSE:SAIPARENT: -38.89
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sai Parenteral's (NSE:SAIPARENT) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sai Parenteral's's PE Ratio (TTM) for today is calculated as:
Sai Parenteral's's share price for today is ₹569.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sai Parenteral's's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was ₹0.374.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sai Parenteral's EV-to-FCF Related Terms
Sai Parenteral's EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's EV-to-FCF Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
EV-to-FCF
0.00
0.00
0.00
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
EV-to-FCF
0.00
0.00
0.00
0.00
NSE:SAIPARENT vs LLY, JNJ, ABBV: EV-to-FCF Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's EV-to-FCF falls into.
Sai Parenteral's's current Enterprise Value is ₹27,006 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sai Parenteral's's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was ₹-694 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's (NSE:SAIPARENT) has a EV-to-FCF of -38.89 as of Aug. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sai Parenteral's and its competitors. According to the industry distribution chart, Sai Parenteral's ranks #999999 out of 565 companies in the Drug Manufacturers industry.
Is Sai Parenteral's' EV-to-FCF too high?
Sai Parenteral's' current EV-to-FCF is -38.89. Based on the distribution chart, Sai Parenteral's ranks #999999 out of 565 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #999999 out of 565 companies for EV-to-FCF. This places Sai Parenteral's in the lower half of its industry. The industry median EV-to-FCF is 21.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.83, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sai Parenteral's and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current EV-to-FCF is -38.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current EV-to-FCF of -38.89. The current EV-to-FCF is -38.89. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current EV-to-FCF is -38.89 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
